ROXRO Announces FDA Accepts For Review NDA For ROX-888 For The Management Of Acute Moderate To Severe Pain (Medical News Today)
ROXRO announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its lead investigational prescription drug candidate, ROX-888, for the management of acute moderate to severe pain.

Galderma Wins FDA Approval For Vectical Ointment, A Novel Topical Therapy For Mild-To-Moderate Plaque Psoriasis (Medical News Today)
Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration (FDA) has approved Vectical (calcitriol) Ointment 3mcg/g, a unique vitamin D3 product for the treatment of mild-to-moderate plaque psoriasis in adults. Psoriasis is a chronic skin disorder that affects 2 to 3 percent of the U.S. population.